Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $272.78M
• Dividend Yield: N/A
• Average Volume (3M): 101.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 47,233,948
• 10 Day Avg. Volume: 169,902
• 30 Day Avg. Volume: 101,050
• PEG Ratio: 0.16
• Price to Book (P/B): 6.21
• Price to Sales (P/S): 513.72
• P/FCF Ratio: -4.61
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 467.51
• Enterprise Value/Gross Profit: 759.71
• Enterprise Value/Ebitda: -3.23
• 1Y Price Target: $34.75
• Price Target Upside: 501.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.57
• Revenue Forecast (FY): $8.46M

• Rating: 46 Neutral
• Price Target: $7.00 ▲(21.11% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is primarily weighed down by deteriorating financial performance (revenue collapse, widening losses, persistent cash burn, and negative equity). Technicals are only modestly supportive with neutral momentum and mixed trend signals. Valuation is constrained by negative earnings, and recent corporate events are mixed with a meaningful program setback despite some pipeline progress.

Positive Factors

Proprietary RNAi platform & pipeline

Silence’s proprietary RNAi platform supports multiple clinical-stage programs, with divesiran designated first-in-class and prioritized. A diversified pipeline built on a core technology creates structural optionality, spreads development risk and supports sustained partner interest and long-term value creation.

Low leverage / minimal debt

Very low reported debt reduces interest burden and refinancing risk, giving the company structural financial flexibility. For a cash-burning biotech, minimal leverage preserves optionality to fund programs via partnerships or equity without near-term debt constraints, supporting survivability over months.

Partnerable Phase‑3 ready asset

A Phase‑3 ready asset that’s explicitly positioned for partnering materially improves options for non-dilutive funding and commercialization support. Partnering can transfer late‑stage development cost, regulatory execution and commercial risk, strengthening long-term viability without relying solely on internal capital.

Negative Factors

Heavy cash burn

Sustained operating and free cash flow losses of roughly $62M in 2025 create persistent financing needs. This structural cash burn increases dilution or partner dependency risk, shortens runway absent new funding, and constrains the firm’s ability to advance multiple programs concurrently over the next 2–6 months.

Revenue collapse & volatile fundamentals

A near-total revenue collapse indicates the company no longer has predictable internal income to offset R&D spend. This structural volatility forces reliance on milestone payments, grants or financings, undermining financial stability and increasing execution risk for sustaining pipeline progression.

Partner withdrawal / program setback

AstraZeneca returning SLN312 rights is a structural setback: it removes a large partner’s development and funding capacity, increases Silence’s resource burden to advance or re‑partner the program, and reduces external validation—raising execution and financing risk for that asset.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Silence Therapeutics generates revenue through multiple streams, including collaborations and partnerships with pharmaceutical companies for the development of RNA-based therapies. The company often engages in licensing agreements that provide upfront payments, milestone payments based on the progress of drug candidates, and royalties from any resulting sales of products developed through these collaborations. Additionally, Silence Therapeutics may receive funding through grants or government programs aimed at supporting innovative healthcare solutions. Their strategic partnerships with larger pharmaceutical entities enhance their financial stability and expand their research capabilities, contributing significantly to their earnings.

Silence Therapeutics Financial Statement Overview

Summary

Very weak and volatile fundamentals: 2025 revenue collapsed (~$0.6M vs ~$43.3M in 2024) while net loss widened (~-$88.6M). Cash burn remains heavy (operating/FCF about -$62.3M), and equity turned negative (~-$62.3M), raising financing risk despite minimal debt.

Income Statement

Results show a sharp deterioration in 2025 with revenue collapsing to ~$0.6M from ~$43.3M in 2024 (down ~97.8%), indicating very high volatility. While gross margin held up (~61.5% in 2025 vs ~72.7% in 2024), profitability remains deeply negative with large losses (net loss ~-$88.6M in 2025 vs ~-$45.3M in 2024), reflecting heavy ongoing cost structure relative to the current revenue base. Overall, the income statement profile is weak and unstable, even by biotech standards.

Balance Sheet

Leverage appears very low (debt is minimal across periods and the debt-to-equity ratio is near zero in recent years), which is a clear strength. However, the balance sheet weakened materially in 2025 as stockholders’ equity turned negative (~-$62.3M vs +$134.0M in 2024), signaling that accumulated losses have eroded the capital base. Total assets declined as well (to ~$131.4M from ~$202.6M), reducing financial flexibility despite limited debt.

Cash Flow

Cash generation is consistently negative in recent years, with operating cash flow around -$62.3M in 2025 (worse than -$39.4M in 2023) and free cash flow also about -$62.3M in 2025, indicating ongoing cash burn. Free cash flow deterioration in 2025 (down ~10.9%) adds pressure. Although free cash flow and operating cash flow broadly track net losses (i.e., losses translate into real cash outflows), the business still appears dependent on external funding to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	559.00K	43.26M	25.38M	21.66M	12.41M
Gross Profit	344.00K	31.45M	15.06M	8.19M	4.96M
EBITDA	-60.80M	-48.99M	-49.78M	-60.44M	-45.42M
Net Income	-88.61M	-45.31M	-43.27M	-50.33M	-39.41M
Balance Sheet
Total Assets	131.44M	202.63M	119.45M	107.50M	96.19M
Cash, Cash Equivalents and Short-Term Investments	85.11M	147.33M	68.79M	71.14M	73.54M
Total Debt	-160.00K	117.00K	346.00K	446.00K	137.00K
Total Liabilities	51.31M	68.61M	97.45M	85.43M	87.67M
Stockholders Equity	46.24M	134.02M	21.99M	22.07M	8.53M
Cash Flow
Free Cash Flow	-62.33M	-67.85M	-39.40M	-57.59M	7.39M
Operating Cash Flow	-62.27M	-67.64M	-39.35M	-57.04M	9.19M
Investing Cash Flow	-35.70M	-21.97M	16.43M	-20.50M	11.71M
Financing Cash Flow	11.16K	142.09M	25.16M	52.58M	41.45M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.78
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Negative. The current price of 5.78 is below the 20-day moving average (MA) of 6.16, above the 50-day MA of 5.50, and below the 200-day MA of 5.82, indicating a neutral trend. The MACD of 0.29 indicates Positive momentum. The RSI at 46.44 is Neutral, neither overbought nor oversold. The STOCH value of 16.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$526.89M	―	274.58%	―	―	-1072.48%
ABEO	47 Neutral	$252.16M	3.92	53.18%	―	―	―
SLN	46 Neutral	$272.78M	-3.24	―	―	―	―
GALT	46 Neutral	$184.41M	-8.32	32.59%	―	―	18.82%
HUMA	45 Neutral	$164.10M	-3.93	853.54%	―	―	82.23%

Silence Therapeutics Corporate Events

Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results

On 5 March 2026, Silence Therapeutics reported fourth-quarter and full-year 2025 results, highlighting clinical progress across its siRNA pipeline and an updated corporate presentation. The company said enrollment in its Phase 2 SANRECO trial of divesiran for polycythemia vera had been expedited, bringing topline data forward to the third quarter of 2026 and underscoring divesiran as its highest-priority, first-in-class program.

Silence also confirmed its Phase 3–ready Lp(a)-lowering candidate zerlasiran is positioned for partnering, while AstraZeneca shared positive Phase 1 data for dyslipidemia drug SLN312 but opted on 4 March 2026 not to develop it further, returning global rights to Silence. The group reported promising preclinical data for new obesity and cholesterol programs, board-level changes including the December 2025 appointment of Iain Ross as interim principal executive officer, and a sharply wider 2025 net loss of $88.6 million on minimal collaboration revenue, despite flat R&D spend and lower G&A costs.

The most recent analyst rating on (SLN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.